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The genus Corynebacterium consists of nearly seventy species and is closely related to the
genera Mycobacterium, Nocardia, and Rhodococcus. The characteristic traits of
Corynebacteria include cells that are shaped like straight rods with clubbed ends, as well as
an extra cell wall layer consisting of mycolic acids covalently bound to the peptidoglycan
layer which adds an additional layer of protection against antibiotics. Corynebacteria are
very well studied and outstandingly important for the large scale biotechnological
production of amino acids and nucleotides.[1] Moreover, Corynebacteria produce several
pathogens that affect humans and livestock. Toxins produced by C. diphtheriae and C.
ulcerans cause diphtheria, a highly contagious respiratory infection in humans,[2] or
diphtheria-like symptoms,[2–3] respectively. C. pseudotuberculosis causes “cheesy gland”
disease in goats and sheep resulting in significant economic losses.[2, 4] Moreover, while
rare, many other Corynebacteria species have also been shown to cause infections.
Therefore, elucidating the functional roles of uncharacterized proteins from Corynebacteria
is of high biomedical and economic importance.
Protein CG2496 from Corynebacterium glutamicum (UniProtKB ID: Q6M3G5, Q8NNC9;
Gene ID: CG2496, Cgl2275) is predicted to be an integral membrane protein comprised of
684 amino acids, where the N-terminal and C-terminal polypeptide segments relative to a
single transmembrane helix are extracellular and cytoplasmic, respectively. In the NCBI
RefSeq and UniProtKB[5] databases, CG2496 is annotated as a chromosome segregation
ATPase, but there is currently no experimental evidence for this particular annotation.
Homologous proteins are found in genomes of 43 other species of Corynebacteria. A
significant portion of the N-terminal domain of CG2496 (residues 63–171) belongs to the
TPM domain (named after proteins TLP18.3, Psb32 and MOLO-1) family (Pfam[6]
accession: PF04536), which currently contains 3,085 protein sequences from 1,821 species,
including bacteria, plants, protozoa and lower metazoa, such as nematodes and lancelets.
Two TPM domain-containing proteins, TLP18.3 from A. thaliana and Psb32(Sll1390) from
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Synechocystis sp., were shown to be involved in the photosystem II (PSII) repair cycle.[7]
Phosphatase activity was reported for TLP18.3,[7b] however, the measured enzymatic
activity levels were very low. In C. elegans, the TPM domain protein MOLO-1 acts as a
modulator of the levamisole-sensitive acetylcholine receptor (L-AChR), but the function of
TPM domain proteins in other organisms is still unknown. The Northeast Structural
Genomics Consortium (NESG; http://www.nesg.org) recently determined the solution NMR
structure[8] of the TPM domain of CG2496 comprising residues 41-180 (PDB ID: 2KPT;
NESG target ID: CgR26A) which revealed a distinct architecture and provided the first
structural representative for PF04536.
Here we describe the identification of low molecular weight compounds binding to the
extracellular N-terminal domain of protein CG2496 from C. glutamicum using an NMR-
based screening approach (FAST-NMR).[9] We expect that the newly identified compounds
will also support future functional characterization of protein CG2496. Furthermore,
assuming that protein CG2496 plays an important role for proliferation of C. glutamicum,
we investigated to which extent one of the compounds, that is, methiothepin, inhibits cell
growth.
1D 1H NMR screening of the FAST-NMR library of 460 low molecular weight compounds
resulted in 13 initial hits which showed broadening of 1H NMR peaks in the presence of
CG2496(41-180) (Table 1). Specific interaction with CG2496(41-180) was revealed by
assessing chemical shift perturbations in 2D [15N,1H]-HSQC spectra recorded for
CG2496(41-180) in the presence of each of the 13 compounds. Additionally, 5 more
compounds from the library, which did not show line-broadening in the 1D 1H NMR screen,
were evaluated using the 2D [15N,1H]-HSQC screen. These compounds were selected to test
hypotheses of CG2496(41-180) function. Of the 18 total compounds screened by 2D
[15N,1H]-HSQC, 10 induced minor perturbations of a small number (<7) of 2D [15N,1H]-
HSQC peaks. Only one compound, methiothepin, induced a significant number (~25) of
chemical shift perturbations in the 2D [15N,1H]-HSQC spectrum of CG2496(41-180)
(Figure 1). An NMR titration of CG2496(41-180) with methiothepin determined a
dissociation constant (KD) of 54 ± 19 μM. Intriguingly, residues exhibiting significant
chemical shift perturbations upon the binding of methiothepin are strongly conserved within
the TPM domain family and are part of a mostly neutral and hydrophobic surface cleft
(Figure 2), which was previously predicted as the putative active site.[8] Every compound
that induced a chemical shift perturbation in the 2D [15N,1H]-HSQC showed a perturbation
for Asp56, while 10 of 11 of these compounds showed perturbations for Tyr53. These two
residues are also found in the predicted active site. Notably, methiothepin is a serotonin
receptor antagonist commonly used as an United States food and drug administration (FDA)
approved antipsychotic drug.[10]
Despite the available three-dimensional structure and similarity with TPM domains of
known function, the function of the CG2496(41-180) domain remains unknown. Sequence
similarity searches with BlastP[11] identify only uncharacterized proteins from
Corynebacteria, while searches for structurally similar proteins with PDBeFold[12] and
DALI[13] identify several phosphatases and the C-terminal domain of an alanyl-tRNA
synthetase. However, our binding results did not indicate any interaction with typical
phosphatase substrates, such as O-phospho-L-serine. The STRING[14] database indicates
relationships with primarily hypothetical proteins, however a gene encoding a dGTP
hydrolase and a gene encoding a histone N-acetyltransferase are loosely associated with
CG2496(41-180). Furthermore, a comparison of the CG2496(41-180)-methiothepin binding
site to a database of protein-ligand binding sites using CPASS[15] did not result in any hits
above a 30% similarity threshold, which is the minimum score used to consider two proteins
to have structurally and functionally similar binding sites.[15b]
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Next, assuming that protein CG2496 plays an important role for C. glutamicum, we
investigated if methiothepin inhibits cell growth. A disk diffusion assay (Figure 3) shows
that methiothepin does indeed inhibit the growth of C. glutamicum. Additionally, a
comparative minimum inhibitory concentration (MIC) test for methiothepin was performed
for C. glutamicum and S. aureus, which does not possess a homolog of CG2496. C.
glutamicum can only grow in media with up to 20 mM methiothepin. Conversely, S. aureus
is able to grow at higher methiothepin concentrations of at least 40 mM. The low solubility
of methiothepin in complex cell culture media prevented the use of higher concentrations
and the determination of a reliable MIC value. However, the growth inhibition of C.
glutamicum by methiothepin and the corresponding lack of activity against S. aureus
suggests CG2496 is the in vivo target of methiothepin. Correspondingly, methiothepin
would be expected to be active against other Corynebacteria containing a homolog of
CG2496.
A tiered ligand-affinity screen using the FAST-NMR approach revealed that methiothepin,
an FDA approved drug, binds to CG2496(41-180) and also inhibits the growth of C.
glutamicum. The presence of CG2496 homologs in Corynebacterium spp. pathogens (e.g.,
the genomes of C. ulcerans, C. diphtheriae, and C. pseudotuberculosis encode homologs of
CG2496 with 46%, 38%, and 43% sequence identity, respectively) suggests that
methiothepin may bind to these proteins as well and may also act as an antibiotic for these
species. These results identify the functionally uncharacterized CG2496 protein and its
homologs as novel targets for drug discovery, and methiothepin as a potentially a lead
compound to develop a new line of antibiotics against Corynebacteria.
Experimental Section
Details of the FAST-NMR ligand affinity screens, the CG2496(41-180)-methiothepin NMR
titration experiment, the generation of the of CG2496(41-180)-methiothepin complex
structure, and the disk diffusion assay are provided in the Supporting Information.
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Figure 1.
An overlay of 2D [15N,1H]-HSQC spectra of free CG2496(41-180) (black) and
CG2496(41-180) bound with methiothepin (gray). The chemical structure of methiothepin is
displayed in the lower right.
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Figure 2.
a) The CG2496(41-180)-methiothepin complex generated by AutoDock where residues with
significant chemical shift perturbations are colored red. b) ConSurf[16] residue conservation
surface representation of the CG2496(41-180)-methiothepin complex where highly
conserved residues are magenta and poorly conserved residues are cyan. c) UCSF
Chimera[17] hydrophobicity surface representation of the CG2496(41-180)-methiothepin
complex where the hydrophilic surface is blue and hydrophobic surface is orange. d)
Delphi[18] electrostatics surface representation of the CG2496(41-180)-methiothepin
complex where the positively-charged surface is blue and negatively-charged surface is red.
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Figure 3.
Disk diffusion assay. C. glutamicum was plated and grown in the presence of a) a disk
soaked with water and b) a disk soaked with an aqueous solution containing 400 μM
methiothepin.
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Table 1
List of compounds from the FAST-NMR screen that bind CG2496(41-180)
Compound Name 1D Hitsa 2D Hitsb Perturbed Residuesc
N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide X X Y53, N56, V168
4-methylpyrazole X X Y53, N56, V168
Bay 11–708 X X Y53, N56, V168
histamine X X Y53, N56, V168
methiothepin X X Y44, L46, Y53, N56, T58, G62, V79, V90, D96, T104, N111, G112,
G114, V116
adenine X X Y53, N56
1-methylimidazole X X Y53, N56, V168
ethacridine X X L46, Y53, N56, T58, F149, L162, V168
adenosine-5'-triphosphated X N56, T58
serotonind X Y53, N56, T58
adenosine-5'-monophosphated X Y53, N56, V168
a
Indicates compounds that exhibited line broadening in 1D 1H NMR screen in the presence of CG2496(41-180)
b
Indicates compounds that caused peak perturbations in the 2D [1H,15N]-HSQC of CG2496(41-180)
c
Identity of the residues that were significantly perturbed (>1 standard deviation from mean perturbation) in the 2D [1H,15N]-HSQC of
CG2496(41-180)
d
These compounds were evaluated in the 1D 1H NMR screen but exhibited no line broadening. Evaluated in 2D [1H,15N]-HSQC screen to test
potential CG2496(41-180) functions.
ChemMedChem. Author manuscript; available in PMC 2015 February 01.
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Experimental Section 
CG2496(41-180) samples 
Two samples of CG2496(41-180) were received from the Northeast Structural 
Genomics Consortium (NESG; http://www.nesg.org; NESG ID: CgR26A), where one 
sample was at natural abundance and the other was uniformly 15N-labeled. The 
structure of the protein was previously deposited in the RCSB PDB as 2KPT.[1] Amino 
acid chemical shift resonances for CG2496(41-180) were collected from the Biological 
Magnetic Resonance Data Bank (http://www.bmrb.wisc.edu).[2] 
  
Function-based compound library and mixtures 
The compound library consists of functional ligands such as metabolites, substrates, 
inhibitors, and cofactors that have been shown to bind proteins and influence activity.[3] 
The compound library contains 460 active compounds that can be found in the 
BioScreen database (http://bionmr.unl.edu/ligands). Stock solutions for each compound 
are stored at -80 °C in either dimethyl sulfoxide-d6 or D2O at a concentration of 20 mM. 
In order to minimize the number of NMR samples during the 1D line-broadening screen, 
the compounds are combined into 117 mixtures that consist of 3-4 compounds each, 
which has been determined to be the optimal 1D NMR mixture size.[4] The mixtures are 
created using equal volumes of individual compound stock solution, leading to a final 
concentration of 5 mM per ligand in each mixture. 
 
NMR ligand-based screen 
The NMR samples for a 1D line-broadening screen were prepared in 10 mM d19-bis-Tris 
2 
 
buffer at pH 6.5 in 99.99% D2O and 11.1 μM TMSP-d4 to act as a chemical shift 
reference. Each sample had a 100 μM final concentration for each ligand in the mixture 
while the CG2496(41-180) protein (natural abundance) concentration was 10 μM. The 
1D 1H NMR spectra were collected on a Bruker 500 MHz Avance spectrometer with a 
triple-resonance, Z-axis gradient cryoprobe and BACS-120 sample changer using a 1D 
1H excitation sculpting pulse sequence to improve water suppression and signal-to-
noise. The data was processed using ACD 1D NMR Processor. The spectra of the 
ligand mixtures with protein were visually compared to the spectra of the ligand mixtures 
without protein. A mixture was flagged as a potential binding event if the peak intensity 
of the protein-ligand sample decreased relative to the ligand-only sample.[5] The 
potential binding ligand was identified by comparing the broadened peak to reference 
spectra of ligands known to be in the mixture. 
 
NMR target-based screen 
For each compound that showed binding in the 1D line-broadening screen, an NMR 
sample of that compound in the presence of protein was prepared. The NMR sample 
consists of the ligand at 400 μM concentration and the CG2496(41-180) protein (15N-
labeled) at 30 μM concentration in a 10 mM bis-Tris buffer at pH 6.5 and 10% D2O. The 
2D [15N,1H]-HSQC experiments were collected on the same 500 MHz spectrometer 
described above using the WATERGATE and water flip-back pulses for solvent 
suppression. The data was processed using NMRPipe[6] and visualized in CCPNMR 
Analysis (http://www.ccpn.ac.uk). The resulting spectra were overlaid with the spectrum 
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of the free protein, and protein-ligand spectra that showed significant perturbations of 
NMR peaks relative to the free protein spectra were designated as binders.[7] 
 
Generation of CG2496(41-180)-methiothepin costructure 
The ligand (methiothepin) that caused the greatest magnitude chemical shift 
perturbations (CSPs) in the 2D [15N,1H]-HSQC screen was used to define the 
consensus binding site using in-house program CSP-Consensus. The three 
dimensional structures of both the ligand and the protein were prepared for docking 
(correcting for missing atoms) using UCSF Chimera.[8] AutoDock 4.2.3[9] with the 
AutoDockTools 1.5.4[9c, 10] (http://mgltools.scripps.edu) graphical interface was used to 
calculate 120 CG2496(41-180)-methiothepin costructures. The AutoDock grid was set 
to encompass the consensus-binding site identified from the in-house CSP-Consensus 
program with a grid spacing of 0.375 Å. The docking was performed using the 
Lamarckian genetic algorithm with a population of 300 and 2,500,000 energy 
evaluations. The docked structure that best agreed with the experimental CSPs from 
the 2D [15N,1H]-HSQC experiment was identified using in-house program 
AutoDockFilter 2.0.[11] 
 
NMR titration of CG2496(41-180) with methiothepin 
The titration analysis was performed with a 333 μM U-15N, 5%-13C-labeled CG2496(41-
180) sample (5.7 mM MES buffer, pH 6.5 with 57 mM NaCl, 1.7 mM CaCl2, 0.007% 
NaN3, 3 mM  DTT, 17 μM DSS, and 10% D2O) and six increasing concentrations of 
methiothepin (0 μM, 94.5 μM, 185.2 μM, 314.7 μM, 589.3 μM, and 1045.5 μM) 
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dissolved in the same buffer. The 2D [15N, 1H]-HSQC experiments were collected on a 
Varian 600 MHz DD2 instrument equipped with a cryogenic probe. The data was 
processed using PROSA,[12] referenced to internal DSS, and visualized in CCPNMR 
Analysis (http://www.ccpn.ac.uk). The magnitude of the CSPs observed for each ligand 
concentration was used to determine the dissociation constant (KD) for the CG2496(41-
180)-methiothepin complex using the following binding isotherm:[13] 
 
CSPobs  CSPmax
( D  [ ]  [ ])  √( D  [ ]  [ ])  ( [ ][ ])
 [ ]
                                   (1) 
 
where [P] is the protein concentration, [L] is the ligand concentration, CSPmax is the 
maximum chemical shift perturbation observed for a fully bound protein, CSPobs is the 
observed chemical shift perturbation at each ligand concentration. A least squares fit of 
[Eq. (1)] to the normalized CSPs for ten perturbed amino acid residues (Glu51, Tyr53, 
Val90, Asp96, Thr104, Ala110, Asn111, Gly112, Gly113, Val116) was used to 
determine the average dissociation constant of methiothepin binding to CG2496(41-
180). 
 
Disk diffusion assay 
The antimicrobial disk diffusion assay was performed by spreading ~105 bacteria onto a 
Petri dish containing Mueller Hinton agar. After letting the Petri dish dry for 10 minutes, 
Whatman 3MM Chr paper disks (6 mm diameter) impregnated with 400 μM 
methiothepin or water (negative control) were placed in the center of the Petri dishes. 
The Petri dishes were incubated for 12 hours at 37°C and photographed. 
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